Exhaled air contains numerous substances, often in extremely low concentrations. The development of sensitive detection techniques has made it possible to examine the composition of exhaled air in relation to a variety of airway diseases and other disorders. In this book, an overview of current cutting-edge breath analysis techniques and their clinical applications is provided for the clinician. The various contributions give a fascinating perspective of a future where new, highly sensitive methodologies will enable clinicians to diagnose and monitor a wide variety of diseases merely by taking.
Breathborne biomarkers carry information on the state of human health, and their role in aiding clinical diagnosis or in therapeutic monitoring has become increasingly important as advances in the field are made. Breathborne Biomarkers and the Human Volatilome, Second Edition, provides a comprehensive update and reworking of the 2013 book Volatile Biomarkers, by Anton Amann and David Smith. The new editing team has expanded this edition beyond volatile organic compounds to cover the broad field of breath analysis, including the many exciting developments that have occurred since the first edition was published. This thoroughly revised volume includes the latest discoveries and applications in breath research from the world's foremost scientists, and offers insights into related future developments. It is an ideal resource for researchers, scientists, and clinicians with an interest in breath analysis. - Presents recent advances in the field of breath analysis - Includes an extensive overview of established biomarkers, detection tools, disease targets, specific applications, data analytics, and study design - Offers a broad treatise of each topic, from basic concepts to a comprehensive review of discoveries, current consensus of understanding, and prospective future developments - Acts as both a primer for beginners and a reference for seasoned researchers
Volatile organic compounds (VOCs) in exhaled breath, sweat or urine carry much information on the state of human health. The role of VOCs in clinical diagnosis and therapeutic monitoring is expected to become increasingly significant due to recent advances in the field. Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine includes the latest discoveries and applications for VOCs from the world's foremost scientists and clinicians working in this emerging analytic area.
Breath Analysis presents state-of-the-art research in this specialized field, also offering guidance on how best to design the technology and conduct analysis. The book primarily focuses on the diagnosis of lung cancer, asthma and Chronic Obstructive Pulmonary Diseases. The reliability, consistency and utility of the results from breath analysis depends on exhaled breath sampling procedures and tools, gas sensor array technology (sensing material and transducer), and finally, medical pertinence and interpretation. The book gives step-by-step procedures and discusses best practice solutions for problems in sample collection, sensor technology, clinical assessment, medical interpretation and data analysis. The book's primary audience would include biomedical engineers and medical doctors, but it is also useful for hospital technicians, hospital and biomedical SME leading figures, and those in PhD level Engineering and Medicine. - Presents an overview of existing breath analysis technology, along with their pros and cons - Provides a tool for mapping, bridging and translating different approaches and available devices - Covers best practices and procedures for exhaled breath collection
Volatile organic compounds (VOCs) in exhaled breath, sweat or urine carry much information on the state of human health. The role of VOCs in clinical diagnosis and therapeutic monitoring is expected to become increasingly significant due to recent advances in the field. Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine includes the latest discoveries and applications for VOCs from the world's foremost scientists and clinicians working in this emerging analytic area. - Appeals to a multidisciplinary audience, including scientists, researchers, and clinicians with an interest in breath analysis - Features the latest scientific research and technical breakthroughs in the diagnostic and therapeutic aspects of volatile organic compounds - Includes case presentations documenting applications in multiple areas of human health and safety
This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.
The 3rd World Congress on Genetics, Geriatrics, and Neurodegenerative Disease Research (GeNeDis 2018), focuses on recent advances in genetics, geriatrics, and neurodegeneration, ranging from basic science to clinical and pharmaceutical developments. It also provides an international forum for the latest scientific discoveries, medical practices, and care initiatives. Advanced information technologies are discussed, including the basic research, implementation of medico-social policies, and the European and global issues in the funding of long-term care for elderly people.
This book investigates the emerging use of biomarkers as a diagnostic tool for the identification of patients with an abnormal condition or as a tool for staging the extent of disease, as an indicator of disease prognosis. Chapters in Part I focus on biomarkers for cancer, including breast cancer and pancreatic cancer, as well as circulating microRNA profiling in cancer biomarker discovery. Chapters in Part II focus on biomarkers of other diagnoses/diseases, including sepsis, childhood renal diseases, pulmonary diseases, Alzheimer's, leishmaniasis, and heart failure. This book investigates the emerging use of biomarkers as a diagnostic tool for the identification of patients with an abnormal condition or as a tool for staging the extent of disease, as an indicator of diseases prognosis. The book is of considerable importance for a broad range of people including researchers, clinicians, and university students.
Biomarkers in Toxicology, Second Edition, is a timely and comprehensive reference dedicated to all aspects of biomarkers that relate to chemical exposure and their effects on biological systems. This revised and completely updated edition includes both vertebrate and non-vertebrate species models for toxicological testing and the development of biomarkers. Divided into several key sections, this reference volume contains new chapters devoted to topics in microplastics, neuroimmunotoxicity and nutraceuticals, along with a look at the latest cutting-edge technologies used to detect biomarkers. Each chapter contains several references to current literature and important resources for further reading. Given this comprehensive treatment, this book is an essential reference for anyone interested in biomarkers across the scientific and biomedical fields. - Evaluates the expansive literature, providing one resource covering all aspects of toxicology biomarkers - Includes completely revised chapters, along with additional chapters on the newest developments in the field - Identifies and discusses the most sensitive, accurate, unique and validated biomarkers used as indicators of exposure - Covers special topics and applications of biomarkers, including chapters on molecular toxicology biomarkers, biomarker analysis for nanotoxicology, development of biomarkers for drug efficacy evaluation, and much more
Advances in long-term improvement and outcomes of patients with kidney disease will require the use of novel biomarkers to identify patients at high risk for kidney disease and to diagnose kidney disease early for effective treatment. A biomarker is a substance found in the blood, body fluids or tissues that provides a measure of normal biological or pathological processes or response to pharmacological compounds or drugs. There are a wide variety of biomarkers including but not limited to mRNA, proteins and peptides, and lipid molecules. In AKI, important pathophysiological processes such as inflammation, apoptotic and necrotic cell death and, tubule regeneration may be reflected in blood or urine. An array of candidate markers along with clinical information in long-term clinical studies with appropriate analytical methodologies will likely provide prognostic information. Despite well-known limitations, currently the most widely used biomarkers for the early diagnosis of CKD and AKI are proteinuria, serum creatinine and blood urea nitrogen. Most clinicians are aware that serum creatinine and blood urea nitrogen are poor biomarkers due to inherent characteristics of these molecules and handling by the kidney. Creatinine is secreted and urea nitrogen is reabsorbed by the renal tubules. Many endogenous substances interfere in the assay for creatinine. Serum creatinine and urea appear late after acute kidney injury and the serum levels in part depend on the generation (large or small body mass). Acute kidney injury is a non steady state condition thus serum creatinine and urea nitrogen will lag behind kidney injury. For these reasons new biomarkers are imperative. With knowledge of these limitations in use of current biomarkers and the lack of progress in reducing the mortality and morbidity from kidney disease, there has been a great surge of interest in identifying novel biomarkers with a particular emphasis on the early diagnosis of kidney disease. A variety of methods have been employed including transcriptomics, proteomics, gene arrays and lipidomics. Currently, candidate biomarkers have been found in different disorders and have been tested in humans and many candidate biomarkers have yet to be identified. Most studies to date are preliminary and require validation in large multicentre studies followed by commercial assay development validation and testing. This new book outlines the rapid advances made in the field of biomarker development for kidney disease in which a variety of novel molecules have been identified and studied in humans.
